The study also suggested that circFOXK2 can serve as a potential therapeutic target using antisense oligonucleotide (ASO-circFOXK2) which can lead to the suppression of ER-positive BC growth and can be used synergistically alongside tamoxifen. This evidence concerns the gene ESR1 and breast cancer.